A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
A Phase IIIb, Multinational, Open-label, follow-on Trial to C87085 Designed to Assess the Long-term Safety of Certolizumab Pegol, a Pegylated Fab' Fragment of a Humanized Anti-TNF-alpha Monoclonal Antibody, Administered at Weeks 0, 2 and 4, and Then Every 4 Weeks Thereafter, in Subjects With Moderately to Severely Active Crohn's Disease Who Have Participated in Study C87085
Sponsor: PPD Development, LP
Listed as NCT00552344, this PHASE3 trial focuses on Crohn Disease and remains completed. Sponsored by PPD Development, LP, it has been updated 10 times since 2008, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Jun 2025 — Sep 2025 [monthly]
Completed PHASE3
-
Oct 2024 — Jun 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Sep 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jun 2018 — Sep 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
May 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- PPD Development, LP
- UCB BIOSCIENCES GmbH
For direct contact, visit the study record on ClinicalTrials.gov .